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Background/aim: Cystic fibrosis is an autosomal recessive disease with a defect in mucociliary activity that is characterized by recurrent
pulmonary infections. Bacterial agents frequently implicated in airway colonization are Haemophilus influenzae, Staphylococcus spp.,
and Pseudomonas spp. Fungal isolation from sputum is common in adults. However, growth of fungal agent only in sputum culture
in patients with cystic fibrosis is insufficient for the diagnosis of fungal diseases. There is limited data about the clinical significance of
fungal isolation in sputum cultures. The aim of the study was to investigate the clinical outcomes andsignificance of fungal isolation
from sputum samples in adult CF.
Materials and methods: This retrospective study included patients who have been admitted between October 2017 and January 2019
in an adult cystic fibrosis unit. Patients were grouped according to fungal pathogenicity as; fungal disease group, colonization group,
and nonisolated group. The data of the last one year, including demographics, clinical data, laboratory, treatment modalities, results of
cultured bacteria and fungus from sputum samples, respiratory function parameters, frequency of exacerbation, and hospitalizationwere
compared between groups.
Results: A total of 330 sputum samples from 88 adult patients with CF were collected. Patients were divided into 3 groups, the fungal
disease group (n = 10, 11.4%), colonization group (n = 49, 55.7%), and nonisolated group (n = 29, 32.9%). Presence of pulmonary
exacerbation, number of admissions to emergency department, and the number of positive cultures for bacteria from sputum were
higher in the fungal disease group (p = 0.03, p = 0.01 and p < 0.001). The fungal disease group had higher rate of antibiotics by
parenteral routethan other groups (p = 0.001) whereas lung functions were similar. Use of nutritional supplementation and parenteral
antibiotherapy were the factors associated with elevated risk of fungal isolation.
Conclusion: Frequent use of parenteral antibiotics and use of nutritional supplementation were found to be independent risk factors for
fungal isolation from sputum in adult CF.
Key words: Adult cystic fibrosis, sputum, fungi

1. Introduction
Cystic fibrosis (CF) is an autosomal recessive multisystemic
disease characterized by defective chloride (Cl–) channel
transport and frequent respiratory infections leading to
bronchiectasis and bacterial airway colonization later
in life. Over the past years, novel therapeutic agents
have been developed altering the natural course of the
disease and prolonging mean life expectancy of these
patients. This improvement in life expectancy has brought

an ever growing population of CF patients surviving
into adulthood [1,2]. The most important factors that
determine the prognosis, mortality, and morbidity of
this debilitating disease are chronic bacterial airway
infections and respiratory failure secondary to acute
exacerbations. Bacterial agents most frequently implicated
in airway colonization and infection are Haemophilus
influenzae, Staphylococcus spp. and Pseudomonas spp.
Previously, several studies have been conducted to shed
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light on the effects of bacterial infections on disease
progression [3]. Frequent antibiotic and inhaled steroid
use may predispose to orofarengeal and airway fungal
colonizations [3–5]. Isolation of fungal species is more
common among adult CF patients owing to bronchiectasis
and airway colonization in this group that emanates from
chronic pulmonary infections [6,7]. Aspergillus spp. and
Candida spp. have high prevalence in adult CF patients
(8). Aspergillus fumigatus is the most commonly isolated
filamentous fungus from adult patients’ sputum which
varies from 6% to 58% and this variation is explained
by forecast different areas, differences in methods of
culture and difference in climatic conditions [9,10]. The
prevalence of allergic bronchopulmonary aspergillosis
(ABPA) is higher in adulthood than childhood (10.1%
vs. 8.9%) [11]. This condition is diagnosed by presence
of pulmonary infiltrates on chest radiography, detection
of immunoglobulin G (IgG) and immunglobulin E (IgE)
antibodies specific for A. fumigatus, and elevated total IgE
[12]. The clinical significance of isolation of A. fumigatus in
CF patients’ sputum other than ABPA is unknown. Recent
studies have shown that ABPA is likely to be a prognostic
factor for progression of disease and deterioration of lung
function [3,13]. Candida albicans, on the other hand,
is a common yeast that is isolated from sputum in up to
75% of patients with CF [4,9].The importance of Candida
isolation is unknown, although limited studies have shown
that it is related to worsening of lung functions [14,15].
Limited data exists with regards to fungal species and their
potential role in CF lung infections. Moreover, there is lack
of sufficient evidence to implicate fungal colonization or
infection in CF disease progression and clinical outcomes.
It is thought that fungal pathogens will achieve increasing
significance as there are important causes associated with
CF pulmonary infection or deterioration in lung function
[16]. Putting the evidence gap into consideration, the aim of
the present study was to investigate clinical characteristics,
pulmonary functions, and treatment modalities of adult
CF patients that had fungi isolated from their sputum
samples, as well asthe clinical significance of fungal
isolation.
2. Materials and methods
This retrospective cohort study was conducted in the
Department of Chest Diseases, at the Adult Cystic
Fibrosis Unitin the University School of Medicine. The
study was approved by the local ethics committee of
the University of Medical Faculty Hospital (Ankara–
Turkey–22.01.2019/03-25). Ethical approval was obtained
in accordance with the Helsinki Declaration. Data were
collected from patients’ files in the hospital database. Due
to the retrospective nature of the study, informed consent
was not obtained from the patients for the use of medical
data for publication purposes with the approval of the local

1192

scientific committee. All patients’ ID information was kept
confidential.
2.1. Patients
Patients who have been admitted between October 2017
and January 2019 were retrospectively evaluated. The
patient population of the study consisted of all adult
cystic fibrosis patients (ages 18 and older) who were
followed at the study center in the study time period. In
all patients, the diagnosis of CF was determined by clinical
features associated with positive sweat test (chloride> 60
mmol/L) and/or cystic fibrosis transmembrane regulator
(CFTR) mutation analysis. Patients who had a history of
lung or liver transplantation were excluded. All sputum
samples collected from patients during the preceeding
year regardless of whether the presence of pulmonary
exacerbation were analyzed for fungi. Bronchoscopy was
not performed on any patient for sampling and all samples
examined were sputum samples.
Patients were grouped according to fungal
pathogenicity as; fungal disease group, colonization group,
and nonisolated group.
Fungal colonization was defined as the positive fungal
species in ≥1 of sputum cultures without clinical and
radiological infection signs and/or acute decline in lung
functions. Patients with any fungal isolation who have
been evaluated for antifungal treatment, and then who
received antifungal treatment were defined as the fungal
disease group. The nonisolated group included patients
with negative fungal cultures during the previous year.
Decision of the antifungal treatments and the duration
of these treatments were decided on the patient basis
by discussing the clinical, laboratory and radiological
characteristics in the multidisciplinary council (consist of
department of pediatric pulmonology, adult chest diseases,
and infectious diseases).
2.2. Data
The data were collected electronically from the hospital
database.
Patient
demographics,
comorbidities,
diagnosis age, follow up period (months) at adult CF
center, type of mutation, total IgE level, hemoglobin,
leukocyte count, renal and liver function parameters,
hemoglobin A1c (HgA1c) level, systemic and/or inhaled
corticosteroid use, number of antibiotherapy use, route of
antibiotherapy administration (parenteral route), presence
of history of antibiotherapy(regardless of antibiotherapy
duration),number of cultured bacteria and fungus
from sputum samples in the previous year, respiratory
function parameters, and frequency of exacerbation and
hospitalization were recorded from patients’ files. The data
obtained was compared between groups.
2.3. Isolation of fungal and bacterial strains
For mycological cultures, sputum samples were plated on
Sabouraud dextrose agar (SDA) and incubated at 35 ±
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2°C and 25 ± 2°C for 7 days. Identification of the isolated
fungal strains on mycological or bacteriological media (5%
sheep blood agar, MacConkey agar, chocolate agar with
bacitracin, mannitol salt agar, and Burkholderia cepacia
selective agar) at species/species complex level were
performed using conventional mycological methods [17].
All samples were cultured according to the standard
diagnostic laboratory protocol, which included testing for
bacterial organisms that were identified on the basis of
macroscopic and microscopic morphology.
2.4. Statistical analysis
The data were collected from the files of the patients and
the operating systems of the hospital and analyzed using
theSPSS programme v.23.0 (IBM Corp,Armonk, NY,
USA). The normality of variables were examined with the
Shapiro–Wilk test, boxplots, and Q-Q plots. Descriptive
statistics were shown as the median, the 25th, and 75th
percentiles as the normality assumption was not satisfied.
Furthermore, for continuous variables independent three
groups were compared with Kruskal–Wallis variance
analysis, while categorical variables were compared with a
chi-square or a likelihood ratio test. The univariate logistic
regression models were conducted to specify candidate
variables in multiple logistic regression. The variables
which are significant at p < 0.25 were chosen as variables
for multiple logistic regression. Backward elimination
was performed with those variables. The results of final
logistic regression models were represented with odds
ratio (OR), 95% of confidence interval and p-value. The
level of statistical significance was set at a p-value < 0.05.
All reported p-values are 2-sided.

3. Results
During the study period, 88 (97.7%) of the 90 patients
admitted to the Adult CF Center were enrolled (Figure) in
to the study. Age range of the study population was 18–43
years (median 24), and 39 (44.3%) were female. A total
of 330 sputum samples were collected and at least one
positive culture for fungi was collected from 159 (48.1%)
of them. Patients were divided into 3 groups, the fungal
disease group (n = 10, 11.4%), colonization group (n = 49,
55.7%), and nonisolated group (n = 29, 32.9%).
Eighty-four patients (95.5%) have positivity growing
with bacterial species and median number of bacterial
culture pozitivity was 3 (1–21 range). Fifty-nine patients
(67%) had positivity growing with fungal species and
median number of fungal culture pozitivity was 2 (1–15
range). Twenty-six (26/59, 44%) of them had fungal
growth in only one sputum. Both bacterial and fungal
culture positivity were present in 56 (63.6%) patients.
Candida spp. and Aspergillus spp. were the most
common fungi isolated, corresponding, respectively,
to 36 (73%) and 22 (44.9%) in the colonization group,
and 8 (80%) and 6 (60%) in the fungal disease group. At
species level, C. albicans and A. fumigatus were the most
commonly isolated types (n = 30, 61.25% and n = 21,
42.9%, n = 8, 80%, and n = 5, 50%) (Table 1).
Staphylococcus aureus and Pseudomonas aeruginosa
were the two most common bacterial species demonstrating
no difference between the study groups. The third most
common isolate, meticiline resistant Staphylococcus aureus
(MRSA), had a higher proportion despite a lower number

Figure. Flow chart of patients’ distribution.
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Table 1. Fungal and bacterial species isolated from sputum samples in groups.
Fungal colonization
group (n = 49)

Fungal disease
group (n = 10)

Non-isolated
group (n = 29)

All Patients
(n = 88)

p value

36(73.5)
30(61.2)
3(6.1)
4(8.2)
4(8.2)
22(44.9)
21(42.9)
2(4.1)
2(4.1)
1(2)
7(14.3)
0
0

8(80)
8(80)
0
0
0
6(60)
5(50)
0
1(10)
0
0
1(10)
1(10)

NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA

44(50)
38(43.2)
3(3.4)
4(4.5)
4(4.5)
28(31.8)
26(29.5)
2(2.3)
3(3.4)
1(1.1)
7(8)
1(1.1)
1(1.1)

0.67#
0.23#
0.43#
0.04#
0.04#
0.39#
0.68#
0.52#
0.44#
0.65#
0.007#
0.34#
0.34#

9(90)
7(70)
4(40)
0
1(10)
2(20)
2(20)

22(75.9)
18(62.1)
5(17.2)
5(17.2)
1(3.4)
0
0

67(76.1)
52(59.1)
17(19.3)
7(8)
6(6.8)
6(6.8)
3(3.4)

0.53*
0.63*
0.21*
0.06*
0.63*
0.04*
0.04*

Fungi, n (%)
Candida spp.
C.albicans
C.parapsilosis
C.glabrata comlex
C.dubliniensis
Aspergillus spp.
A.fumigatus
A.terreus
A.flavus
A.niger
Penicillium
Saccharomyces cerevisea
Cryptococcus albicus
Bacterium, n(%)
Staphylococcus aureus
Pseudomonas aeruginosa
MRSA
Stenotrophomonas maltophilia
Burcholderia cepacia
Acromobacteria
Nocardia

36(73.5)
27(55.1)
8(16.3)
2(4.1)
4(8.2)
4(8.2)
1(2)

Chi-square test.
Kruskal–Wallis test.
MRSA; methicillin resistant Staphylococcus aureus, NA; not assesment.
#
*

in the fungal disease group (n = 4, 40% vs. n = 8, 16.3%
and n = 5, 17.2%). Acromobacteria and Nocardia were
the least isolated microorganisms, but were the ones more
frequently seen in the fungal disease group compared to
other groups (Acromobacteria; n = 2, 20%, n =4, 8.2%, n=
0 and Nocardia; n = 2, 20%, n = 1, 2%, n = 0, p=0.04, each).
Table 2 summarizes the demographics of the groups
as well as the hospital data, laboratory test results, lung
function parameters and treatment characteristics. Both
groups had similar age, BMI (body mass index) and
comorbidities. ABPA was significantly higher in the fungal
disease group than other two groups (n = 3, 30%, n = 2, 4.1%
and n = 2, 6.8%, p = 0.01). The presence of exacerbation
and number of admission to emergency department in
the preceeding year were significantly higher in the fungal
disease group (presence of exacerbation; n = 9, 90%, n =
22, 44.9%, n = 9, 31%, p = 0.03 and median number of
admission to emergency; 3.5[1–4.25], 1 [1–2],1 [1–2], p
= 0.01), whereas both the number of exacerbation and
hospitalization were similar between all study groups.
Higher C-reactive protein (CRP) and total IgE levels
were seen in the fungal disease group (p = 0.02 and p =
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0.03). There was no difference in respiratory function
parameters between groups. In mutation analysis, the
CFTR locus was examined in 57 (64%) patients. In a total
of 114 CF chromosomes, 31 different mutations were
identified in 105 (92.1%) of the alleles. The most common
mutation was F508del 33 (31.4%), the rate for which was
similar between groups.
The number of positive cultures for bacteria from
sputum in one year was significantly higher in the fungal
disease group (8 [5–13.5], 3 [2–5] and 2 [1–3], p<0.001).
Treatment characteristics and outcomes in both
groups are shown in Table 3. Patients in the fungal
disease group had higher rate of parenteral antibiotherapy
than other groups (n = 8, 80%, n = 17, 34.7% and n = 5,
17.2%, p = 0.001); however, both the number and length
of antibiotherapy were similar between groups.Enteral
nutrition support using high energy feeding solutions with
varying content and amount based on individual need was
significantly higher in the colonization group than in the
nonisolation group (n = 24, 49%, n = 4, 40% and n = 6,
20.7%, p = 0.04). Other maintenance drug use was similar
between groups.
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Table 2. Comparison of clinical characteristics of groups.
Fungal colonization Fungal disease
group (n = 49)
group (n = 10)

Non-isolated
group (n = 29)

p value*

Sex, n (%)
Female

22 (44.9)

6 (60)

11 (37.9)

0.47

Age, median (min-max)

24 (21–27,5)

24,5 (20.75–26.25) 23 (20–25.5)

0.7

BMI, mean (SD)

20 (18.5–22.5)

20.5 (16.75–22.5)

21 (19–25)

0.47

Age of diagnosis (month), median (min-max)

12 (3–144)

18 (2.75–63)

9 (3–150)

0.85

Follow up duration (month), median (min-max)

36 (12–48)

36 (15–51)

36 (12–48)

0.15

Additional diseases, n(%)
DM
Asthma
Hepatobiliary disorder
Chronic sinusitis
GERD
Osteoporosis
Pancreatic insufficiency

6 (12.2)
6 (12.2)
8 (16.3)
10 (20.4)
6 (12.2)
7 (14.3)
45 (91.8)

2 (20)
4 (40)
7 (70)
0
0
1 (10)
10 (100)

1 (3.4)
4 (13.8)
9 (31)
4 (13.8)
4 (13.8)
3 (10.3)
28 (96.6)

0.22
0.13
0.002
0.11
0.27
0.84
0.37

ABPA, n (%)

2 (4.1)

3 (30)

2 (6.8)

0.01

History of pulmonary exacerbation, n (%)

22 (44.9)

9 (90)

9 (31)

0.03

Pulmonary exacerbation(≥2), n (%)

8 (53.3)

4 (66.7)

4 (21.1)

0.05

Hospitalization/year, median (min-max)

1 (1–2)

1 (1–3)

1 (1–2.5)

0.95

Admission to emergency department/year, median
(min-max)

1 (1–2)

3.5 (1–4.25)

1 (1–2)

0.01

0.38

Hospital data

Laboratory and respiratory function parameters, median (min-max)
Eosinophil (%)

1.6 (1.15 –2.5)

1.35 (0.6–215)

1.3 (0.65–2.15)

Hemoglobin (g/dL)

14 (13–15)

13.4 (12.7–14.2)

14.8 (13.8–15.8) 0.05

BUN (mg/dL)

12.2 (9.9–15.2)

10.15 (7.34–14.55) 12.4 (10.15–16) 0.2

Creatinin (mg/dL)

0.67 (0.56–0.73)

0.5 (0.41–0.74)

0.66 (0.54–0.76) 0.22

AST (IU/mL)

20 (17–26.5)

18.5 (17–21.75)

22 (19–26.5)

ALT (IU/mL)

18 (13–26.5)

15.5 (10.75–20.75) 20 (15.5–27.5)

0.21

Total bilirubin (mg/dL)

0.5 (0.38–0.68)

0.41 (0.35–1.71)

0.48 (0.4–0.68)

0.63

CRP (μg/dL)

0.89 (0.4–2.29)

1.73 (1.41–5.47)

1 (0.45–2.2)

0.02

Total IgE (μg/mL)

50.4 (15.05–153)

156 (74.6–454)

58.5 (18.5–144) 0.03

HgA1c (%)

5.6 (5.1–6.1)

5.8 (5.3–6.5)

5.7 (5.3–6)

0.31

FEV1 (%)

60 (39.5–85.5)

47.5 (32.75–82.25) 72 (43–88)

0.36

FEV1/FVC ratio

70 (62.5–77.5)

82.5 (63.25–93.25) 70 (65–81.5)

0.21

Positive bacterial cultures/year, median (min-max)

3 (2–5)

8 (5–13.5)

0.00

2 (1–3)

0.11

Kruskal–Wallis test
BMI; body mass ındex, CRP; C-reactive protein, AST; aspartate aminotransferase, ALT; alanin aminotransferase, GERD; gastroesophageal
reflux disease, ABPA; allergic bronchopulmonary aspergillosis, BUN; blood urea nitrogen, HgA1c; hemoglobin A1c, FEV1; forced
expiratory volume in 1 s, FVC; forced vital capacsity.
*

Multivariate logistic regression identified nutritional
supplementation (CI: 1.17–11.96, p = 0.01), parenteral
antibiotherapy (CI: 1.27–12.63, p = 0.02) in the preceeding

one year as factors that significantly elevated risk of fungal
isolation in patients who had fungal growth on culture in
comparison to those without any fungal isolation (Table 4).
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Table 3. Treatment characteristics.
Fungal colonization
group (n = 49)

Fungal disease
group (n = 10)

Non-isolated
group (n = 29)

p value*

Antibiotherapy/year, median (min-max)

1 (1–3)

2 (2–4)

1.5 (1–2.25)

0.08

Parenteral antibiotherapy, n (%)

17 (34.7)

8 (80)

5 (17.2)

0.001

Maintenance drug use, n (%)
Dornase α
Inhaled colistin
Inhaled bronchodilatator
Inhaled corticosteroid
ICS+LABA
Inhaled mannitol
Inhaled antibiotic
Nutritional supplementation
Multivitamin

43 (87.8)
3 (6.1)
18 (36.7)
3 (6.1)
11 (22.4)
4 (8.2)
20 (40.8)
24 (49)
40 (81.6)

10 (100)
1 (10)
5 (50)
0
7 (70)
1 (10)
6 (60)
4 (40)
9 (90)

23 (79.3)
1 (3.4)
10 (34.5)
2 (6.9)
5 (17.2)
0
15 (51.7)
6 (20.7)
19 (65.5)

0.12
0.73
0.67
0.53
0.68
0.12
0.43
0.04
0.15

Kruskal–Wallis test.
ICS+LABA;inhaled corticosteroid and long acting beta2 agonist combination.
*

Table 4. Multivariate logistic regression analysis: comparison of patients with fungus isolated (colonization/
disease) and non-isolated group.
Risk factor

Beta

Standard
error

Odds
ratio

Confidence
interval (%95)

p value

Use of parenteral antibiotics

1.38

0.57

3.86

[1.27–12.63]

0.02

Nutritional supplementation

1.36

0.54

3.75

[1.17–11.96]

0.01

Hemoglobin

–0.46

0.19

0.70

[0.43–0.91]

0.10

FEV1

–0.002

0.01

0.99

[0.70–1.24]

0.55

FEV1; forced expiratory volume in 1 s.

4. Discussion
This study is the first to investigate the effects of sputum
fungal isolation on clinical characteristics of adult patients
with CF from a tertiary care center in Turkey. The primary
finding was that several clinical and laboratory variables
were related to fungal infection, including history of
exacerbation, admission to emergency department
with acute clinical deterioration, ABPA, number of
positive cultures for bacteria, and history of parenteral
antibiotherapy use in the preceedingyear. While the
presence of fungi in the sputum of CF patients had
generally been considered clinically of less important
during the past decade, recent availability of improved
culture methods lead to more frequent isolation of fungal
species from sputum samples, and they are increasingly
coming to the attention of clinicians [8,10,16]. Recent
studies have pointed to the evidence that fungal
colonization increases with age. This may be explained by
association of severe disease with exacerbations secondary
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to bacterial infectionsthat require antibiotic use [3,7,18–
20]. However, growth of fungal agent only in sputum
culture in CF patients is not sufficient for the diagnosis
of fungal diseases. In the past decade, Chotirmall et al.
presented that C. albicans colonization is related with
increased exacerbations requiring inpatient treatment and
FEV1 decline. In the same study, isolation of Candida spp.
from the first sputum sample was linked to a subsequent
high rate of hospitalization which was independent of the
frequency of antibiotherapy or exacerbation rates [14].
A retrospective clinical study showed that Aspergillus
isolated from airways was associated with an increased risk
of pulmonary exacerbations requiring hospital admission
and with a lower FEV of 1%. The authors of this study
also highlighted that the presence of Aspergillus was an
independent risk factor for hospitalization [13]. In the same
study, majority of fungal infections caused by Aspergillus
and Candida were associated with presence of pulmonary
exacerbation and emergency admissions as reported by
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previous studies albeit there was no association for fungal
colonization. Fungal isolation was clinically inclined to,
although not associated with exacerbation frequency.
Fungal colonization or fungal infection did not affect the
number of hospitalizations during the preceeding year.
In our study population, there was no association
between lung function and either fungal colonization
or disease. Current evidence is conflicting in that, while
several studies support our findings [5,10,19,21] others
report an association with lower FEV1 [13–15,22].
In a cross sectional study by Milla et al., there was no
association between A. fumigatus colonization and lung
function. These findings have been shown to be due to
demographic characteristics such as age and sex, which
were related to disease severity [7]. A recent systematic
review reported that two studies [23,24] found significant
association with worse FEV1 in patients with CF and
impaired glucose tolerance [25]. In our study, presence of
CF related diabetes mellitus and HgA1c levels were similar
between the study groups. When these results are taken
into consideration, our findings are not significant and this
can be explained by demographic characteristics and other
confounder factors affecting FEV1.
ABPA, a hypersensitivity reaction to A. fumigatus
antigens and/or Aspergillus isolated from sputum, is an
important complication of CF leading to deterioration of
lung function [22]. There is no certain recommendation
about antifungal therapy in CF patients with ABPA.
Although it has been indicated an advantageous approach
that it may lead to reduced doses of corticosteroids,
comprehensive randomized controlled studies are
needed[26].Among our 7 patients diagnosed with ABPA,
A. fumigatus have been isolated in 2 of them, C. albicansin
2, and both fungi in 2 patients, and no fungal isolation
receiving in 2 patients. One of the them received systemic
steroid and four received antifungal treatment.
The most important causative agents of respiratory
exacerbations in CF patients, who are known to have
rich diversity of fungal and bacterial microorganisms,
are bacterial organisms, especially Pseudomonas species
in adults [27]. Although there are opposing views
[28–30] such as bacterial species suppressing fungal
growth in culture, it is known that the use of broad
spectrum antibiotics is a predisposing risk factor that
potantiatesfungal pathogenicity in these patients [22,31].
In our study, the positive correlation between the number
of positive cultures for bacteria from sputum samples and
fungal infection is in agreement with this observation.
Staphylococcus aureus and Pseudomonas aeruginosa
were the two most common species isolated from the
sputum of patients, being recovered from 76.1% and
59.1% of the patients, respectively. This prevalence rates
are similar to other reports but more studies reported

Pseudomonas as the most commonly isolated species in
adult CF patients [9,32]. The equilibrium between lung
microbioma may be impaired in patients from whom P.
aeruginosa is isolated, resulting in a spiralling of fungal
isolation, as reported by some authors. On the other hand,
a number of studies suggested the use of wide spectrum
antibiotics for bacterial infections. This approach may
explain this finding and that fungal colonization/
infection risk is reduced with antipseudomonal antibiotic
use [33]. At this point, the question arises whether it is
bacterial coinfection or suppression of bacterial growth
by antibiotics that explains the excess in fungal isolation.
The answer explaining this cause-effect relationship, thus
far, remains elusive. In our study, isolation of MRSA
and P. aeruginosa and parenteral antibiotic use were in
excess in the fungal disease group. However, it is not clear
whether the decision on starting antifungal treatment
was influenced by high rate of exacerbation and bacterial
isolation in this group. In other words, it is not clear which
came first, the chicken or the egg?
Among isolated fungi, Candida and Aspergillus
showed the highest prevalance in patients, representing
50 and 31%, respectively. The most frequently isolated
Candida species when all patient groups are taken into
consideration were C. albicans (43%), C. glabratacomplex
(4.5%), C. dubliniensis (4.5%), and C. parapsilosis (3.4%).
While A. fumigatus (29.5%), A. flavus (3.4%), A. terreus
(2.3%), and A. niger (1.1%) comprised the most common
Aspergillus species. This distribution is similar to findings
in several other studies [4,9,10,35].
CF patients frequently receive antibacterial agents
through several routes of administrations including
orally, parenterally and via aerosols for the treatment of
exacerbations and bacterial eradication. Various studies
conducted have reported different results regarding
the treatment characteristics and effects on fungal
pathogenicity. To our knowledge, one extensive study
was conducted in the form of a retrospective cohort study
comprising 16,096 patients from the CF Foundation
Patient Registry with a follow-up period of 6 years. This
study reported that chronic therapies, including inhaled,
oral and intravenous antibiotics, macrolides, and inhaled
corticosteroids were also associated with an increased risk
of persistent Aspergillus isolation. However, when applied
to the adult subpopulation, only oral steroid use become
a significant risk factor for persistant Aspergillus[22].
In a large multicenter (69 centers) double-blinded
placebo-controlled study incoorporating 595 CF patients,
inhaled tobramycin users had a significantly high rate
of Aspergillus isolation [35].Another study by Bargon et
al. on adult CF patients, found that prolonged oral and
inhaler antibiotic treatment as well as administration via
both routes predisposed to Aspergillus colonization, a
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finding that was later reproduced by Vrankrijker et al. in
a cohort study that also included adult patients [10,19].
Factors affecting Candida colonization examined by Noni
et al., revealed the independent effect of the duration of
both inhaled antibiotic and inhaled corticosteroid use on
Candida colonization, but they did not find an association
with annual intravenous antibiotic courses [5]. In contrast,
a retrospective study from France found that the number
of antibiotic use via oral, inhaled or intravenous routes
in 1and 5 years had no effect on Aspergillus spp. isolation
[36]. Similarly, a longitudinal study concluded there
is no association between recurrent broad spectrum
antibiotherapy and Candida colonization [37]. On the
other hand, a prospective observational study of 26 adult
patients with CF reported that the use of short term
intravenous antibiotics targeting Pseudomonas reduced the
presence of Aspergillus in sputum [33]. Our current study
concluded that antibiotic use via intravenous route was
associated with fungal disease but not fungal colonization.
Multivariate analysis confirmed that intravenous route
of administration may both be predictive risk factors
for fungal colonization increasing fungal pathogenicity
risk approximately three-fold. Our results with results
of previous studies, showed that duration and fequency
of antibiotic use, oral or inhaled, did not affect either
colonization or isolation of fungus [22,36]. Maintanence
use of inhaled steroids, bronchodilators or a combination
of both were not associated with fungal colonization or
infection in the adult population.
Increased energy needs due to chronic pulmonary
infections and excessive respiratory effort as well
as insufficient energy intake and malabsorbtion are
important causes of malnutrition in CF patients [38]. A
recent study indicated that poor nutritional status was
an independent risk factor for ABPA [36]. Prior studies
have shown that comorbidities such as liver failure and
inadequate nutrition are often associated with fungal
airway colonization [39,40]. In accordance with this, we
demonstrated that fungal isolation was associated with
nutritional supplementation. Nutritional support in CF
patients may be a predictor of fungal colonization. At our
center, enteral supplementation with high-energy adult
feeding solutions to cover daily nutritional requirements
in excess of 20% is afforded to CF patients in need.
Additionaly, early enteral nutrition support is provided
to all patients with inadequate oral intake, even if they
have normal BMI. This may explain the observed lack of
association between BMI and fungal isolation. A recent
retrospective study that included 257 patients identified
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concominant fungal and bacterial colonization to be
independently associated with liver disease in CF patients
[41]. In this study, fungal colonization was significantly
higher in patients with hepatobiliary disease as opposed
to other comorbidities. However, there are limitied studies
and more epidemiological research is needed to investigate
pathogens and to clarify the predisposing factors.
One important limitation of this study is that delineating
fungal colonization and fungal disease is challenging.
Whereas previous studies defined fungal colonization as
the presence of fungal species in ≥50% of sputum cultures
collected in one year independent of clinical findings, in
our study, we used the term to refer to fungal growth not
associated with any findings suggestive of infection. This
approach may have accounted for the discrepancy between
our results and those reported by other authors. Another
restriction of our study was the fact that ABPA patients
were included in our study because fungal isolation is
not a mandatory criterion for ABPA diagnosis. As such,
ABPA and elevated IgE levels were more common in
the fungal disease group. Being a single-center study on
a homogenous population obviously had implications
on the rate of fungal isolation since this is also affected
by ethnic and regional factors. However, ours is the first
established center that deals with adult CF patients that
has the largest number of patients in Turkey, the number
of which is expected to grow up in coming years. Lastly,
the sample size was insufficient for the evaluation of the
distribution of certain variables betweenstudy groups and
the data of antifungal treatments could not be evaluated
due to the retrospective nature of the study.
In conclusion, frequent use of parenteral antibiotics
and use of enteral feeding supplements were found to be
independent risk factors for fungal colonization or disease
in adult CF patients. It seems that antibiotic use leads to
fungal overgrowth; however, it is not clear which patients
would benefit from antifungal treatment. Studies including
larger patient population and expanded data on antifungal
treatment outcomes are needed to clearly understand the
clinical importance of fungal isolation.
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